Bone Abstracts

The aim of the research: To investigate the effect of combined calcium and vitamin D therapy (calcium 1000 mg, vitamin D 400 IU) on 25(OH)D level and concentration of bone turnover markers in patients with systemic postmenopausal osteoporosis.

Methods: 20 women with systemic postmenopausal osteoporosis were examined. The average age of the patients was (63.0 (59.00; 68.00)) years. The study was performed during winter season to exclude the influence of seasonal factors on 25(OH)D level in the blood serum. Before and the end of the sturdy it was evaluated the intensity of vertebral pain syndrome in the thoracic and lumbar spine and quality of life by EuroQoL-5D and ECOS-16.

25(OH)D iPTH and bone turnover markers were evaluated by Elecsys 2010 analyzer (Roche Diagnostics, Germany).

Results: Three month therapy didn’t significantly change the intensity of vertebral pain syndrome in the thoracic and lumbar spine and didn’t significantly influence quality of life by EuroQoL-5D and ECOS-16.

Combine therapy with calcium and vitamin D increased 25(OH)D level from (35.86 (29.43; 54.14)) to (46.07 (33.75; 52.54)) nmol/l (P<0.05). Bone formation marker decreased from (49.67 (29.40; 54.14)) to (46.50 (38.86; 56.08)) pg/ml (P>0.05). Bone resorption marker (β-CT_x) at baseline was (0.513 (0.305; 0.646)) ng/ml and reached (0.437 (0.344; 0.555)) ng/ml at the end of sturdy (P>0.05).

Conclusions: Prescriptions of combine therapy of calcium and vitamin D in patients with systemic postmenopausal osteoporosis during three winter months leads to significant increasing 25(OH)D level in blood serum (P<0.05) and do not significantly influence the bone formation and resorption markers (P>0.05).